iView Therapeutics Inc Profile last edited on: 7/16/2023
CAGE: 7HLG3
UEI: YMCPKUN173R3
Business Identifier: Novel formulations to overcome drug delivery issues 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 12
County: Middlesx
Congr. District: 12
County: Middlesx
Public Profile
IVIEW Therapeutics is a specialty pharmaceutical company focused on topical drug and medical device development with specific emphasis on the therapeutic areas of ophthalmology, dermatology, Otolaryngology and Gynecology. Previously located in the Pennsylvania Biotechnology Center of Bucks County (Doylestown, PA) the firm has now relocated to Cranbury NJ. The firm has also set up a joint-venture corporation in Wuhu, China for development efforts in the China market.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2019 | 2 | NIH | $579,745 | |
| Project Title: In-Situ Gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis | ||||
| 2017 | 1 | NIH | $323,349 | |
| Project Title: Novel Extended Release Povidone Iodine Ophthalmic Drop for Viral Conjunctivitis | ||||
Key People / Management
Bo Liang -- Co-founder, President & Director
John J Baldwin -- Co-Founder and Director
Kathleen Czupich
Xiang Jin
Yong Lu
Hany Michail -- Chief Medical Officer
Gang Wei -- Ocular Drug Delivery Formulation Specialist
John J Baldwin -- Co-Founder and Director
Kathleen Czupich
Xiang Jin
Yong Lu
Hany Michail -- Chief Medical Officer
Gang Wei -- Ocular Drug Delivery Formulation Specialist
Company News
There are no news available.
